Stryker (SYK): Mako Growth Supports a Buy
Stryker posted 7.7% organic sales growth and 10.3% adjusted EPS growth in Q3, with Mako and broad segment momentum supporting a Buy rating despite a rich valuation.

Stryker posted 7.7% organic sales growth and 10.3% adjusted EPS growth in Q3, with Mako and broad segment momentum supporting a Buy rating despite a rich valuation.

Stryker (SYK) merits a Buy rating for moderate-risk investors with a medium-term horizon. The thesis rests on 7.7% organic sales growth in Q3 2026, 10.3% growth in adjusted EPS to $3.52, a 6.5% to 7.0% full-year organic sales outlook, and a product portfolio led by the Mako robotics platform. The main constraint is valuation: Stryker trades at 31.5x trailing earnings despite $12.26B of net debt and a Q3 result that management said fell short of expectations.
Stryker's growth engine remains broad. MedSurg and Neurotechnology produced Q3 sales of $3.7B and organic growth of 9.1%, while Orthopaedics generated $2.9B of sales and organic growth of 5.9%. Mako installations reached a company record in Q2, and the installed base has supported more than 2.5 million procedures across 47 countries.
The investment case is strongest when operational execution and valuation discipline work together. Q3 adjusted operating margin was 26.2%, up 60 basis points year over year, and the company repurchased $1.0B of stock during the quarter. At a reference price of $329.67, the shares offer upside toward the analyst target of $362.62, but the margin of safety is limited enough to favor staged buying rather than an aggressive entry.
Stryker (SYK) is a medical technology company founded in 1941 and headquartered in Portage, Michigan. It employed approximately 56,000 people and sold products through company subsidiaries, branches, dealers, and distributors in about 61 countries. Chairman and CEO Kevin A. Lobo leads the company.
The company operates through two reporting segments: MedSurg and Neurotechnology, and Orthopaedics. Its portfolio spans surgical equipment, endoscopy, patient handling, emergency care, neurovascular products, hospital communication systems, joint replacements, trauma products, and robotic-assisted surgery.
MedSurg and Neurotechnology is the larger segment. It produced $15.65B of revenue in 2025, or 62.3% of company sales, versus $13.52B and 59.8% in 2024. The segment includes instruments, endoscopy, medical products, vascular products, neurotechnology, connected operating-room tools, patient handling, and emergency care.
The segment delivered 9.1% organic growth in Q3 2026. Q2 provided more detail: U.S. endoscopy organic sales rose 10.2%, U.S. medical organic sales increased 13.1%, and international MedSurg and Neurotechnology organic sales grew 10.5%. U.S. vascular organic sales fell 6.7% in Q2 because of a peripheral vascular supply disruption.
Orthopaedics generated $9.47B of revenue in 2025, or 37.7% of total sales. Q3 organic growth was 5.9%, led by increased unit volume. In Q2, U.S. knee sales grew 6.2%, U.S. hip sales rose 4.9%, U.S. trauma and extremities increased 12.5%, and U.S. Orthotech grew 9.2%.
The segment mix gives Stryker two distinct growth channels. MedSurg and Neurotechnology adds exposure to hospital capital equipment, connected care, and neurovascular products, while Orthopaedics adds recurring procedure demand from joint replacement, trauma, and extremities. MedSurg's larger share also means execution in that segment has an outsized effect on consolidated results.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Mako is Stryker's most important flagship platform. The system has supported more than 2.5 million procedures globally and has installations across 47 countries. Its applications now cover hip, knee, spine, and shoulder procedures, turning a single robotic platform into a broader surgical ecosystem.
Stryker reported its best-ever second quarter for Mako installations in both the U.S. and international markets, while utilization rates across the installed base continued to rise. U.S. knee growth of 6.2% and Orthotech growth of 9.2% in Q2 provide direct evidence that the platform is contributing to current revenue rather than existing only as a long-term concept.
The product roadmap has broadened the platform. Mako RPS received a full commercial launch in the U.S., Mako Shoulder reached full commercial launch on Mako 4.0, and Mako Revive expanded the hip platform into more difficult primary hip cases and hip revisions. The commercial advantage comes from linking capital equipment, implants, software, surgeon training, and procedure data in one workflow.
Stryker's competitive advantage is built on product breadth, sales coverage, installed equipment, and a steady launch cadence. Q2 launches and approvals included Mako RPS, the Encompass total ankle replacement system, the Pangaea Trauma Plating System in Europe, and the Sonopet 3 Ultrasonic Aspirator.
The company also continues to refresh established franchises. Triathlon Gold and the Triathlon Medial Stabilized Insert were moving toward full commercial launches, while the SURPASS Elite flow diverter supported growth in the hemorrhagic portfolio. These launches spread innovation across orthopaedics, instruments, neurotechnology, and vascular products.
The moat is practical rather than purely technological. Hospitals and surgeons that adopt Mako, connected operating-room systems, patient-handling products, or procedure-specific implants build training and workflow familiarity around Stryker equipment. The company's 56,000 employees, global distribution, and broad hospital relationships reinforce that installed-base advantage.
Innovation still carries execution risk. Stryker competes intensely in every product line, and its 10-K identifies regulatory requirements, product liability, cybersecurity, and pricing pressure as material risks. A strong launch pipeline therefore supports the premium business model only when the company converts approvals into installations, utilization, and recurring procedure revenue.
Stryker entered 2026 with an operational disruption tied to a cybersecurity incident. Management said production was ramping back toward normal levels, but manufacturing losses, idle costs, remediation work, and information-technology spending weighed on the year. Q2 organic sales growth of 9.0% showed that demand remained intact while production recovered.
Peripheral vascular created a separate supply issue in Q2. A disruption at a plant supporting the Inari business produced an elevated backorder and lost sales. Management said the backorder would reach a manageable level by the end of Q3. Q3 company sales still reached $6.52B, up 7.7%, although the lower full-year guidance shows that the recovery did not remove all execution pressure.
The operating model has meaningful leverage. Q2 adjusted gross margin was 66.0%, up 60 basis points year over year, and adjusted operating margin was 27.4%, up 170 basis points. Q3 adjusted operating margin was 26.2%, up 60 basis points. Tariff-related benefits, product mix, cost discipline, and lower adjusted SG&A supported the improvement, while raw-material costs and cyber remediation remained offsets.
Stryker operates in medical devices, durable medical equipment, surgical technology, and connected hospital systems. Market estimates place the global durable medical equipment market at $231.85B in 2025 and $319.54B by 2031, with a 5.4% projected compound annual growth rate. A broader North American medical devices market estimate reaches $342.85B by 2032 from $218.26B in 2025.
The faster portion of the market is tied to connected and electronics-heavy equipment. The global medical electronics market was estimated at $11.11B in 2024 and projected at $15.71B in 2029, representing 7.2% growth across that period. Stryker's SmartCare, Vocera, care.ai, navigation, robotics, and connected operating-room products give it exposure to this faster-moving category.
Stryker's 7.7% organic growth in Q3 exceeded the mid-single-digit growth rates attached to broad equipment markets. That premium reflects Mako adoption, hospital capital demand, new products, and Stryker's exposure to medically necessary procedures. The 6.5% to 7.0% full-year organic sales outlook sets a more measured pace after the cybersecurity disruption and the Q3 result.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
Stryker sells to doctors, hospitals, ambulatory surgery centers, and other healthcare facilities. Its customer base includes large hospital systems that purchase capital equipment, surgeons who select implants and robotics systems, and clinical teams that use recurring consumables such as skin-preparation products, endoscopy products, and emergency-care equipment.
The portfolio is weighted toward high-acuity, medically necessary, and emergent care. Management reported stable U.S. procedural trends in Q2 and said it had not observed meaningful changes in procedure volumes despite commentary about softness in discretionary surgery. Q3 organic growth of 7.7% provides a later operating datapoint supporting continued customer demand.
Customer purchasing behavior is shifting toward productivity, capital efficiency, and care outside the traditional hospital. Stryker identified elevated demand for ProCuity beds and SmartCare products, while management highlighted ambulatory surgery centers as an important setting for hips, knees, and the wider portfolio. That mix favors vendors that can combine equipment, implants, software, and service.
In orthopaedics, Stryker identifies Zimmer Biomet (ZBH), Johnson & Johnson (JNJ) through DePuy Synthes, and Smith+Nephew (SNN) as its main large global rivals in joint replacement, trauma and extremities, and robotics. Stryker's presence across both orthopaedics and MedSurg creates a broader product footprint than a single-category orthopaedic supplier.
In MedSurg and Neurotechnology, the competitive set includes Medtronic (MDT), Boston Scientific (BSX), Baxter (BAX), B. Braun, Olympus (7733.T), Karl Storz, and Getinge (GETI-B.ST), depending on the product category. Competition is therefore fragmented by procedure, but Stryker faces established global companies with regulatory expertise, hospital contracts, and specialized sales forces.
Stryker's differentiator is the combination of breadth and execution. MedSurg and Neurotechnology organic growth of 9.1% in Q3 exceeded Orthopaedics organic growth of 5.9%, while the Mako installed base adds a platform effect inside orthopaedics. The trade-off is that broad competition and hospital consolidation can pressure pricing, contract terms, and sales-force productivity.
Aging demographics support Stryker's procedure categories. The U.S. population over age 80 is projected to rise from 4.2% in 2024 to 5.2% by 2029, while CEO Kevin Lobo cited 12,000 people reaching age 65 each day. These demographic facts align with demand for joint replacement, trauma care, mobility products, and hospital productivity tools.
Reimbursement remains a central industry pressure. Management discussed proposed changes affecting physician reimbursement for large-joint procedures and described the process as a recurring source of industry noise. The company also identified pricing pressure, healthcare consolidation, tariffs, oil, and other raw materials as factors influencing margins and customer decisions.
Geopolitical exposure is present but has been limited in the reported results. Management said the conflict in Iran had a modest effect on company growth in Q2. Stryker's international organic growth was 8.9% in Q2, led by markets including Australia and New Zealand, Germany, Canada, South Korea, Japan, India, and Brazil. Currency, trade restrictions, and regional regulatory rules remain relevant to that global footprint.
Net debt stands at $12.26B, so Stryker’s balance sheet is solid but not especially conservative for a company trading at 31.5x trailing earnings.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q3 adjusted operating margin reached 26.2%, up 60 basis points year over year, while adjusted EPS rose 10.3% to $3.52.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management is guiding to 6.5% to 7.0% full-year organic sales growth, signaling that the company expects momentum to continue beyond Q3.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →At 31.5x trailing earnings and a reference price of $329.67, Stryker still screens as expensive even with an analyst target of $362.62.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The shares closed around $329.67 against an analyst target of $362.62, leaving upside but not enough margin of safety for an aggressive entry.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Stryker (SYK) remains one of the stronger diversified franchises in medical technology. Its $25.12B of 2025 revenue, 7.7% Q3 organic growth, 26.2% Q3 adjusted operating margin, and Mako platform establish a credible foundation for continued earnings growth.
The risks are measurable rather than theoretical. Stryker is managing cyber-related costs, a peripheral vascular supply disruption, reimbursement pressure, raw-material exposure, and $16.36B of debt. Reported Q3 net earnings fell 12.3%, even as adjusted earnings grew, making the quality and durability of margin expansion important for the medium-term outcome.
A Buy rating is appropriate because the operating platform remains stronger than the recent disruptions. Investors gain the most favorable risk-reward at $320 or below, while $360 marks the report's fair value estimate and prices in much of the demonstrated growth. Stryker does not need heroic assumptions to compound earnings, but the shares do require patience and valuation discipline.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime

Stryker Corporation (SYK) rises after a sharp post-earnings selloff, helped by above-average trading volume and rebound buying. The move follows a Q3 miss and lower full-year guidance, so investors are weighing whether the stock is stabilizing or just bouncing.

Stryker Corporation (SYK) falls sharply after hours after reporting solid Q3 results but trimming full-year guidance. The medical-device giant still posted growth, yet investors focused on the lower outlook, premium valuation, and earnings quality concerns.

Stryker’s Q2 execution, Mako robotics momentum, and raised full-year outlook support a Buy, though valuation leaves limited room for error. Cybersecurity, supply disruption, and tariff pressure keep the risk profile disciplined.